Colossal Biosciences
Colossal Biosciences develops genetic engineering and computational-biology technology for conservation and de-extinction projects.
The Company
Colossal Biosciences was founded to develop technologies that can support de-extinction and conservation efforts. Its work spans computational biology, genome engineering, reproductive technology, and species-specific programs involving animals such as mammoths, thylacines, and dodos.
In January 2025, Colossal announced a $200 million Series C led by TWG Global at a $10.2 billion valuation. The investment case rests less on a single species project than on whether the underlying technology can produce durable applications in conservation, animal health, and biotechnology.
Why It Matters
Colossal is an unusual private-market example of a platform-biotech valuation being driven by long-duration scientific optionality. It shows how capital is pricing genomic tools, high-profile research programs, and potential spinout businesses before conventional revenue scale is established.
Valuation History
- $1.5B→2023Series B
- $10.2B→Jan 2025$200M Series C
What Changed
Colossal is founded to develop de-extinction and conservation technologies.
The company raises Series B financing to expand its genetic-engineering work.
A $200M Series C values Colossal at $10.2B.
THE NEXT COMPANY. A CLEARER PICTURE.
Get the next breakdown.
Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.